92276-38-5

Usage

Uses

Used in Medicinal Chemistry and Drug Discovery:
3H-Triazolo[4,5-b]pyridine, 6-bromoserves as a key building block in the synthesis of various pharmaceutical agents and biologically active molecules. Its unique structure allows for the creation of diverse compounds with potential therapeutic applications.
Used in Materials Science:
3H-TRIAZOLO[4,5-B]PYRIDINE, 6-BROMOhas been studied for its potential applications in materials science, where its structural features may contribute to the development of new materials with specific properties.
Used as a Ligand in Coordination Chemistry:
3H-Triazolo[4,5-b]pyridine, 6-bromohas also been explored as a ligand in coordination chemistry, where it can form complexes with metal ions, potentially leading to new catalysts or materials with unique functions.
Used in Chemical Synthesis and Drug Design Research:
Due to its interesting structural features, 3H-Triazolo[4,5-b]pyridine, 6-bromois an attractive target for research and development in chemical synthesis and drug design, where it may inspire the creation of novel compounds with improved pharmacological properties.

InChI:InChI=1/C5H3BrN4/c6-3-1-4-5(7-2-3)9-10-8-4/h1-2H,(H,7,8,9,10)

Upstream product

• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 
• 38875-53-5 5-bromo-pyridine-2,3-diamine 

Downstream Products

• 1313712-18-3 6-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-[1,2,3]triazolo[4,5-b]pyridine 

Relevant academic research and scientific papers

Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase

The new halogenated 1H-triazolo[4,5-b]pyridines and 1H-imidazo[4,5-b]pyridines were synthesised as analogues of known CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi). Their influence on the activity of recombinant human CK2α, CK2α’ and PIM1 kinases was determined. The most active inhibitors were di- and trihalogenated 1H-triazolo[4,5-b]pyridines (4a, 5a and 10a) with IC50 values 2.56, 3.82 and 3.26 μM respectively for CK2α. Furthermore, effect on viability of cancer cell lines MCF-7 (human breast adenocarcinoma) and CCRF-CEM (T lymphoblast leukemia) of all final compounds was evaluated. Finally, three crystal structures of complexes of CK2α1-335 with inhibitors 4a, 5a and 10a were obtained. In addition, new protocol was used to obtain high-resolution crystal structures of CK2α’Cys336Ser in complex with four inhibitors (4a, 5a, 5b, 10a).

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase

Tryptophan 2,3-dioxygenase (TDO2) is a heme-containing enzyme constitutively expressed at high concentrations in the liver and responsible for l-tryptophan (l-Trp) homeostasis. Expression of TDO2 in cancer cells results in the inhibition of immune-mediated tumor rejection due to an enhancement of l-Trp catabolism via the kynurenine pathway. In the study herein, we disclose a new 6-(1H-indol-3-yl)-benzotriazole scaffold of TDO2 inhibitors developed through rational design, starting from existing inhibitors. Rigidification of the initial scaffold led to the synthesis of stable compounds displaying a nanomolar cellular potency and a better understanding of the structural modulations that can be accommodated inside the active site of hTDO2.